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Mutation of the Melastatin-Related Cation Channel,
TRPM3, Underlies Inherited Cataract and Glaucoma
Thomas M. Bennett, Donna S. Mackay, Carla J. Siegfried, Alan Shiels*
Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, Missouri, United States of America
Abstract
Inherited forms of cataract are a clinically important and genetically heterogeneous cause of visual impairment that usually
present at an early age with or without systemic and/or other ocular abnormalities. Here we have identified a new locus for
inherited cataract and high-tension glaucoma with variable anterior segment defects, and characterized an underlying
mutation in the gene coding for transient receptor potential cation channel, subfamily M, member-3 (TRPM3, melastatin-2).
Genome-wide linkage analysis mapped the ocular disease locus to the pericentric region of human chromosome 9. Whole
exome and custom-target next-generation sequencing detected a heterozygous A-to-G transition in exon-3 of TRPM3 that
co-segregated with disease. As a consequence of alternative splicing this missense mutation was predicted to result in the
substitution of isoleucine-to-methionine at codon 65 (c.195A.G; p.I65 M) of TRPM3 transcript variant 9, and at codon 8
(c.24A.G; p.I8 M) of a novel TRPM3 transcript variant expressed in human lens. In both transcript variants the I-to-M
substitution was predicted in silico to exert damaging effects on protein function. Furthermore, transient expression studies
of a recombinant TRPM3-GFP reporter product predicted that the I-to-M substitution introduced an alternative translation
start-site located 89 codons upstream from the native initiator methionine found in eight other TRPM3 transcript variants
(1–8). Collectively, these studies have provided the first evidence that TRPM3 is associated with inherited ocular disease in
humans, and further provide support for the important role of this cation channel in normal eye development.
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Introduction
Mendelian forms of cataract constitute a clinically and
genetically heterogeneous disorder of the ocular lens that occurs
with an estimated prevalence of 1–3 cases per 10,000 births [1,2].
Typically, inherited cataract presents with an early onset ranging
from birth (congenital) or infancy (infantile) into the fourth decade
and, under slit-lamp examination, exhibits considerable pheno-
typic variation with respect to the location, shape, density and
progression of opacities within the lens [3]. Congenital and
infantile forms of cataract are a clinically important cause of
impaired form-vision development (deprivation amblyopia) that
despite surgical intervention can pose a lifelong risk of progressive
visual impairment, notably as a result of glaucoma [4–6]. Cataract
may be inherited either as an isolated lens phenotype, often with
autosomal dominant transmission and high penetrance, or as part
of many genetic syndromes and metabolic disorders (OMIM.org)
involving systemic abnormalities (e.g. galactosemia, MIM230400)
and/or other ocular defects (e.g. anterior segment dysgenesis,
MIM107250). So far, genetic studies have identified over 50 genes
and loci for inherited cataract, with or without other ocular signs,
including those for a-crystallins, b/c-crystallins, a-connexins and
other lens membrane or cytoskeleton proteins, several transcrip-
tion factors (e.g. HSF4, PITX3, MAF), and an increasing
spectrum of functionally diverse genes (e.g. EPHA2, CHMP4B,
TDRD7, FYCO1) [2,7]. Consequently, no clear genotype-pheno-
type correlation has been observed for inherited cataract rendering
both clinical classification and molecular diagnosis challenging.
Transient receptor potential (TRP) channel genes encode a
superfamily of variably selective cation influx channels that
function as polymodal cellular sensors in diverse physiological
processes including the perception of light, temperature, pressure
and pain [8–10]. The TRP superfamily derives its name from the
visually impaired trp-mutant of Drosophila that was found to
exhibit a transient photoreceptor response to steady light rather
than the sustained electroretinogram observed in wild-type flies
[11]. In mammals, 28 TRP channel genes have been identified,
and based on sequence similarity they are divided into six sub-
families, namely; canonical (TRPC1–7), vanilloid (TRPV1–6),
melastatin (TRPM1–8), ankyrin (TRPA1), polycystin (TRPP1–3),
and mucolipin (TRPML1–3) [9]. All TRP proteins share a
predicted transmembrane topology with six-transmembrane do-
mains including the channel pore-forming loop located between
the 5th and 6th domains. The cytosolic N- and C- termini are
variable in length and contain different combinations of functional
sub-domains including; N-terminal ankyrin repeats, calmodulin-
binding motifs, TRP-boxes, coiled-coil regions, and C-terminal
enzyme domains [12]. Functional TRP channels are assembled
from tetramers of identical (homomeric) or similar (heteromeric)
TRP subunits, and exhibit highly variable permeability to Ca2+
and several other monovalent and divalent cations [9]. TRP
channels exhibit wide tissue distribution in both plasma-mem-
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branes and intracellular membranes particularly from brain and
kidney [13–14].
So far mutations in at least ten TRP genes spanning all sub-
families have been associated with over a dozen human genetic
diseases, referred to as ‘channelopathies’ [15–17]. These include
skeletal dysplasias, sensory neuropathies and spinal muscular
atrophies (TRPV4, MIM 605427), kidney diseases (TRPC6, MIM
603652; TRPP1, MIM 601313), mucolipidosis type-IV
(TRPML1, MIM 605248), familial episodic pain syndrome
(TRPA1, MIM 604775), and Olmsted syndrome (TRPV3, MIM
607066). Within the melastatin sub-family, mutations have been
implicated in Guamanian amyotropic lateral sclerosis-parkinson-
ism/dementia (TRPM7, MIM 605692), progressive familial heart
block type-1B (TRPM4; MIM 604559), hypomagnesemia with
secondary hypocalcemia (TRPM6; MIM 602014), and congenital
stationary night blindness (CSNB) in humans (TRPM1, MIM
603576) and in horses homozygous for Leopard Complex (LP) coat
spotting [18–22]. TRPM3 (melastatin-2), which is most phyloge-
netically conserved with TRPM1 (melastatin-1), has not been
unambiguously linked with inherited human disease. Rare
deletions involving TRPM3 have been reported in cases of
Kabuki syndrome and autism, whereas, common non-coding
variants in TRPM3 have been tentatively associated with
longevity and elevated levels of low-density lipoprotein cholesterol
and triglycerides [23–26].
Here we map, identify, and characterize a mutation in TRPM3
associated with inherited cataract and glaucoma linked to human
chromosome 9q.
Results
A new locus for cataract and glaucoma maps to human
chromosome 9
We investigated a 5-generation Caucasian-American pedigree
mostly from the mid-west United States segregating cataract and
glaucoma with autosomal dominant transmission (Figure 1a;
Table S1). Review of ophthalmic records indicated that the
cataract was usually bilateral and generally described as congen-
ital, infantile or developmental, with age-at-diagnosis varying from
birth (congenital) to 35 years, and age-at-surgery in the first eye
ranging from 4 to 40 years. No slit-lamp images of the cataract
were available; however, in affected individual IV:17 from the
pedigree opacities were described as punctate cortical, and in
affected individual V:4 posterior sub-capsular opacities were
documented by slit-lamp examination in the medical record. All
of the family members with cataract had visually significant lens
opacities affecting best corrected visual acuity and underwent lens
extraction. Of the 25 relatives with cataract, 15 (60%) were also
diagnosed with glaucoma. Glaucoma diagnosis was supported by
significantly elevated intraocular pressure (IOP) .30 mm Hg and,
in some cases, consistent visual field and/or optic nerve
abnormalities. We note that our records of current glaucoma
status for two of the undiagnosed individuals (V:10, V:11) are
incomplete due to unsuccessful follow-up attempts. Age-at-
diagnosis for glaucoma ranged from birth into the fifth decade,
and age-at surgery when performed varied from 11-30 years.
Glaucoma was variously described in four individuals (III:16,
IV:18, V:4, V:9) as congenital, infantile, juvenile, or developmen-
tal open-angle by gonioscopic findings. However, in one affected
individual (III:1) chronic angle-closure glaucoma was suspected,
and in two others (III:14, IV:2) secondary glaucoma was
suspected. Typically, cataract was diagnosed before high-tension
glaucoma (IOP.30 mm Hg). However, in one case (III:1)
glaucoma was diagnosed before cataract, and one individual
(III:16) was diagnosed simultaneously with congenital cataract and
glaucoma.
In addition to cataract and glaucoma several other ocular
findings were reported in certain family members (Table S1).
Bilateral persistent pupillary membrane (PPM) was diagnosed in
affected male V:4 (Fig. 1b) and his older sister (V:3). However, the
latter has not been diagnosed with cataract or glaucoma at age 24
years raising the possibility of incomplete penetrance. Retinal
detachment was reported in at least three affected individuals
(IV:2, IV:18, V:9), and in one case (V:10) retinopathy of
prematurity (ROP) was documented. However, the ROP is likely
to be a coincidental finding. Finally, in one individual (V:9), who
was unavailable for genetic testing, the ocular spectrum included
suspected infantile glaucoma, bilateral Haab’s striae (horizontal
breaks in Descemet’s membrane), anterior segment dysgenesis,
megalocornea, mild corectopia, and PPM. However, intra-ocular
pressure (IOP) and fundus (disc) were normal, and cataract was
absent at eight years of age. Overall, while early-onset cataract and
atypical high-tension glaucoma were commonly observed in this
family, other ocular abnormalities that particularly affect the
anterior segment may co-exist.
For genome-wide linkage analysis 24 consenting members of the
family (19 affected and 5 unaffected) were genotyped by means of
a linkage panel comprising 6090 SNP markers uniformly spaced at
an average genetic distance of 0.58 cM. Using parametric two-
point analysis we detected significant evidence of linkage at SNP
markers rs1333342 (pLOD=4.53), rs735914 (pLOD=3.72), and
rs713478 (pLOD=3.45) located on chromosome 9q (Figure S1a).
Similarly, parametric multipoint analysis detected strong evidence
of linkage between SNP markers rs2031197-(,333.4 kb)-
rs1333342 (pLOD=3.31) on 9q (Figure S1b). Haplotype analysis
of the pedigree further identified a common disease interval
spanning the pericentric region (9cen), rs987187-(,46 Mb)-
rs2378592 (chr9: 38,375,215-84,495,227 bp) that co-segregated
with the disease in all affected relatives (Table S2).
To validate the SNP disease interval from the genome-wide
linkage scan, all 36 relatives were re-genotyped with microsatellite
markers. We obtained strong confirmation of linkage to 9q
(Table 1) using markers D9S175 (Zmax = 8.05, hmax = 0), D9S301
(Zmax = 7.59, hmax = 0), and D9S1876 (Zmax = 6.42, hmax = 0).
Haplotype analysis detected an affected female (III:4) and three
of her descendents (IV:4, V:3, V:4) who were recombinant at
D9S284, and three affected females (IV:7, V:6, V:7) who were
recombinant at D9S1859 (Figure 1a). However, no further
obligate recombinants were detected at seven intervening markers
(Table 1), placing the disease locus in the reduced physical interval
D9S1859-(,41.5 Mb)-D9S284.
To further refine the disease interval we have genotyped the
existing critical recombinant individuals (III:4, IV:4, IV:7, V:3,
V:4, V:6, V:7) with additional SNP markers located within the
boundaries of the microsatellite interval using conventional Sanger
sequencing. Critical affected individual V:6 was also found to be
recombinant at SNP marker rs2073478 (G/T), which is located
within ALDH1B1 approximately 1.77 Mb centromeric to
D9S1859 (Table 1). However, no further recombinants were
detected at more centromeric SNP markers indicating that the
disease locus lay in the refined physical interval rs2073478-
(,39.7 Mb)-D9S284 (chr9: 38,396,065-78,086,081 bp).
Our disease interval spans the centromere and excludes the
adjacent locus for autosomal recessive adult-onset progressive
pulverulent cataract (CTPL1/CAAR) that lies in the interval
D9S1123-(,10 Mb)-D9S257 on 9q [27,28]. In addition the gene
coding for Tudor domain containing-7 (TDRD7, Gene ID:
23424), which has recently been associated with autosomal
TRPM3 in Cataract and Glaucoma
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recessive cataract [29], lies approximately 20 Mb telomeric (chr9:
100,174,302-100,258,407 bp) to the disease interval and was
excluded as the causative gene.
Exome and custom-target sequencing identifies a novel
missense mutation in TRPM3
According to the NCBI Map Viewer database (Build 37.3) the
refined disease interval contained over 270 positional candidate
genes, none of which had been previously associated with eye
disease in humans. In order to scan genes in the interval for
mutations we undertook whole-exome and custom-target next-
generation sequencing of an affected individual (III:16) and an
affected-parent-child-unaffected-sibling trio (IV:7, V:5, V:6),
respectively, from the pedigree. For exome sequencing (III:16),
96.2% of total paired-end reads (133,419,338) were mapped to the
genome, and 78% of mapped reads were present in the captured
exome, of which 95.5% achieved a coverage $5X. Similarly, for
custom-target sequencing (IV:7, V:5, V:6), .98% of total reads
(average 22,175,122) were mapped to the target interval on
chromosome 9, and .61% of mapped reads were present in the
captured target of which .98% achieved a coverage of $5X with
no unexpected gaps.
Combined, both strategies identified the same list of four
heterozygous, exonic variants (three non-synonymous and one
frame-shift deletion) within the disease interval in all three index
affected relatives (III:16, IV:7, V:6) that were not present in the
Figure 1. Linkage analysis of autosomal dominant cataract and glaucoma co-segregating in a 5-generation family. (A) Pedigree and
haplotype analysis showing segregation of markers across chromosome 9cen, listed in descending order from the short-arm telomere (9p-tel).
Affected males (filled squares) and females (filled circles) that were diagnosed with cataract and glaucoma are indicated with a + symbol. (B) Ocular
phenotype of affected individual V:4 presenting with high-tension glaucoma and persistent pupillary membrane characterized by fibrous strands
extending from the iris border across the pupil. (C) Partial ideogram of chromosome 9 showing cytogenetic location of the ocular disease locus. Note,
cytogenetic band regions p11.1, q11 and much of q12 are gene-poor centromeric regions, flanked by gene-rich regions in bands p11.2–p13.3 on the
short arm and q13–q21.31 on the long arm.
doi:10.1371/journal.pone.0104000.g001
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unaffected relative (V:5) (Table 2). Of these variants, three had
known reference sequence (rs) numbers cited in the dbSNP or
1000Genomes databases with no known clinical significance
reported. The minor allele frequency (MAF) of two of the non-
synonymous variants, rs143826416 (FAM75A3) and rs41310055
(GDA), were 43.4% and 1.7%, respectively. Both variants were
predicted to be benign using PolyPhen-2, and rs41310055 (GDA)
was also present on the Exome Variant Server (EVS) (http://evs.
gs.washington.edu/EVS). No MAF was retrieved for the frame-
shift variant, rs200487787 (CNTNAP3B), and it was not present
on the EVS. However, Sanger sequencing confirmed that the
frame-shift variant did not co-segregate with disease in the
pedigree (data not shown). Taken overall, these observations
effectively exclude three of the four variants as causative for
disease.
The remaining non-synonymous variant was novel, and
comprised a heterozygous A.G transition that introduced a Fok
1 restriction site located in exon-3 of the gene coding for transient
receptor potential cation channel subfamily M, member-3
(TRPM3). This missense change occurred at nucleotide position
195 from the first base (A) of the translation start codon in the
cDNA sequence for TRPM3 transcript variant-9 (c.195A.G).
Sanger sequencing confirmed the presence of the c.195A.G
change in exon-3 from the three index affected relatives
(Figure 2b), and excluded mutations in other exons and splice-
sites of TRPM3. Allele-specific PCR amplification and Fok 1
restriction fragment length analysis confirmed that the c.195A.G
change co-segregated with affected but not unaffected relatives
across the family (Figure 2c). Moreover, when we tested the
c.195A.G change as a bi-allelic marker with a notional frequency
of 1% in a two-point LOD score analysis we obtained highly
significant confirmation of linkage to TRPM3 (Zmax = 9.51,
hmax = 0.0) (Table 1). Finally, this variant was not detected in a
panel of 192 normal unrelated Caucasian individuals (384
chromosomes) using allele-specific Fok 1 restriction fragment
analysis described in Figure 2c (data not shown). Combined, our
sequence and genotype data strongly suggest that the c.195A.G
transition constituted a causative mutation and not a benign
variant in linkage disequilibrium with the disease.
TRPM3 generates a novel transcript in human lens, and
gains an alternative translation start-site in other TRPM3
transcript variants
The reference sequence for TRPM3 (Gene ID: 80036)
comprises 28 exons that generate at least nine transcript variants
(1–9) encoding nine protein isoforms (a–h, k) by means of
alternative splicing (Figure 3, Table S3). In order to profile
TRPM3 transcript variants expressed in the human lens we
undertook reverse transcript PCR (RT-PCR) and 5-prime rapid
amplification of cDNA ends (59-RACE). In postmortem lens RNA
we detected strong evidence for multiple TRPM3 reference
transcripts (Figure 4). These included transcript variant-9, which
encodes protein isoform-k, and some or all of transcript variants 1–
8, which encode protein isoforms a-h (Table S3). In addition, we
detected abundant levels of a novel transcript variant (GenBank
accession number: KF987075) that substituted exon-1 of variant-9
with an expressed sequence tag (EST, GenBank accession number:
BM712132) previously found in human lens ([30], Figure 4,
Figure S2).
The c.195A.G missense change in TRPM3 transcript variant-
9 identified above occurred at the third base position of codon 65
(ATA.ATG), and was predicted to result in the conservative
substitution of isoleucine-to-methionine (p. I65 M) in TRPM3
isoform-k at the level of protein translation. Notably in the lens
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transcript variant, which encoded a truncated N-terminal domain
compared with isoform-k, the missense change occurred at codon
8 (c.24A.G) shifting the predicted amino-acid substitution
accordingly (p.I8M). The predicted I-to-M substitution represent-
ed a relatively conservative amino acid change with the non-polar
side-group of isoleucine (-C4H9) replaced by the non-polar sulfur-
containing side-group of methionine (-C2H4-S-CH3). However,
cross-species amino-acid alignment of TRPM3 confirmed that the
substituted isoleucine residue is evolutionarily conserved in bony
vertebrates, and is located within a putative calmodulin-binding
motif near the N-terminus (Figure 3, [31]). Further, in silico
missense mutation prediction analysis using the SIFT and
PolyPhen-2 algorithms were consistent with damaging effects on
protein function (Table 2).
In human TRPM3 transcript variant-9, the translation start
codon is located in exon-1, and the c.195A.G (p.I65M) change in
exon-3 (Figure 3). Similarly, in the lens transcript variant the start
codon is located in the EST and the c.24A.G change (p.I8M) is
located in exon-3. By contrast, in human TRPM3 transcript
variants 1–8 the translation start-codon is located at the end of
exon-4 (Figure 3) effectively placing the predicted p.I65M and
p.I8M substitutions in the 59-untranslated region (59-UTR) in-
frame with the native start-codon lying downstream. Interestingly,
the predicted I-to-M substitution is embedded in a partially
consensus Kozak sequence raising the possibility that it functions
Figure 2. Mutation analysis of TRPM3. (A) Sanger sequence trace of the wild-type allele showing translation of isoleucine (I) at codon 65 (ATA) of
variant 1 (isoform k), and at codon 8 of a novel lens variant. (B) Sequence trace of the mutant allele showing the heterozygous A-to-G transition
(denoted R by the International Union of Pure and Applied Chemistry [IUPAC] code) that is predicted to result in the missense substitution of
methionine (ATG) for isoleucine at codon 65 (c.195A.G, p.I65 M) of isoform k, and at codon 8 of a lens abundant isoform (c.24A.G, p.I8 M). (C)
Restriction fragment length analysis showing gain of a Fok I site (59GGATG[9/13]) that co-segregated with affected individuals heterozygous for the A-
to-G transition (175 bp).
doi:10.1371/journal.pone.0104000.g002
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as a novel translation start-site (Figure 5a, Figure S3). In order to
test this possibility we sub-cloned part of the 59-coding sequence
from variant-9 (codons 60–153) into a GFP fusion vector such that
the I-to-M substitution was in-frame with the consensus translation
start-site for GFP located downstream (Figure 5a, Figure S3).
Following transient expression of the mutant (methionine)
sequence in HEK293T cells and immunoblot analysis with GFP
antibody, we detected a soluble antigen (Mr ,39 kDa) that was
,12 kDa larger than the native GFP (,27 kDa, Figure 5b). This
larger antigen was consistent with translation of a TRPM3-GFP
fusion protein starting from the I-to-M substitution site. By
contrast, the ‘wild-type’ (isoleucine) sequence did not produce a
detectable GFP-fusion product (Figure 5b) most likely because
several out-of-frame translation start-codons were present in the
TRPM3 sequence between the I-to-M substitution site and the
translation start-site for GFP (Figure S3). These data predict that,
in heterozygous individuals, the I-to-M change introduces an
alternative translation start-site in transcript variants 1–8, which is
able to compete with the endogenous start-sites potentially
resulting in the addition of 89 amino acid residues to the N-
terminal domain of protein isoforms a–h.
Discussion
In cases where early-onset cataract and glaucoma are co-
inherited, suspicion is first directed toward genes encoding ocular
transcription factors, notably PAX6, FOXE3, PITX3, and MAF
that control development of anterior ocular structures including
the cornea, iris, ciliary-body, iridocorneal angle drainage system
(trabecular meshwork and Schlemms canal) and lens [32–34].
Following exclusion of these and many other candidate genes we
have identified TRPM3 on human chromosome 9q as a novel
gene for autosomal dominant cataract and high-tension glaucoma.
Figure 3. Schematic showing the gene structure of TRPM3. (A) Exon organization, splice variants and protein domains. Exons are indicated by
numbered boxes (1–28), and codon numbers are shown below each coding exon. Translation start and stop sites are denoted by ATG and asterisks,
respectively. Transcript variants are numbered (1–9), and corresponding protein isoforms are indicated by letters (a–h, k). Exons subject to alternative
splicing (1, 2, 8, 15 and 17) are indicated by plus and minus symbols below each exon. (2/2) indicates that the exon is absent from both the
transcript variant and protein isoform. (+/2) indicates that the exon is present in the transcript variant but is not translated. Exon 2, exon 8 and exon
15 are skipped in transcript variant 9 (isoform k). In transcript variants 1–8 (isoforms a–h) exon 2, exon 3 and all of exon 4 except the last 3 bases (ATG)
are non-coding. EST denotes an expressed sequence tag (BM712132) that replaces exon 1 of variant 9, and exon 2 of variants 1–8, joining directly to
exon 3 in a novel lens abundant transcript variant (KF987075). Arrows indicate the orientation and exon location of PCR primers used to amplify and
sequence the 59-ends of TRPM3 transcripts. The micro-RNA gene, MIR204, is located in intron 8. The predicted I-to-M substitution (red) identified in
the family studied here is located in a putative calmodulin-binding (CaM) motif [31] near the N-terminus of isoform k and the novel lens isoform. The
approximate locations of conserved protein domains are indicated: (pfam00520) ion-transport domain; (TRP1–2) transient receptor potential box 1
and 2; (C–C) coiled-coil domain, and (ICF) amino-acid sequence indispensible for channel function [45]. Note that variants 7 and 8 encode short
isoforms h and c, respectively, lacking the conserved domains above. These short cytoplasmic isoforms may play a role in regulation of the full-length
transmembrane isoforms [64]. (B) Amino acid sequence alignment of the N-terminal calmodulin-binding motif of human TRPM3 isoform-k, a novel
human lens isoform, and homologs from other species showing conservation of isoleucine at the site of the predicted methionine substitution (red).
Divergent amino-acid residues are shaded grey.
doi:10.1371/journal.pone.0104000.g003
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The A-to-G mutation discovered in transcript variant-9 (c.195A.
G) was predicted to result in a missense substitution (p.I65M) in
TRPM3 isoform-k that was located within a putative calmodulin
binding motif. However, because of extensive alternative splicing
of TRPM3 transcripts, the A-to-G mutation was also predicted to
cause a missense substitution (c.24A.G; p.I8M) in a novel
TRPM3 transcript abundant in human lens. In both transcript
variants, the I-to-M substitution was predicted in silico to exert
damaging effects on protein function. Moreover, the I-to-M
substitution was predicted in vitro to function as an alternate
translation initiation-site in TRPM3 transcript variants 1–8
resulting in aberrant N-terminal extension of TRPM3 isoforms
a–h. Structure-function analyses of TRPM channels indicates that
the N-terminal and C-terminal domains form a large cytoplasmic
complex that functions in membrane localization, tetrameric
assembly, and ligand interactions [35,36]. Conceivably, abnormal
extension of the N-terminal domain may reduce overall protein
stability and compromise some or all of these functions. While we
cannot exclude loss-of-function defects, these observations raise
the likelihood that the I-to-M substitution triggers deleterious gain-
of-function effects leading to lens opacities, high-tension glaucoma,
and variable anterior segment defects.
In mice, both Trpm3 and its intronically hosted, non-coding
micro-RNA gene (Mir204) are co-expressed in ocular tissues,
particularly the ciliary-body, lens epithelium, and retinal pigment
epithelium [37–39]. Recently, the paired-box transcription factor
gene, Pax6, has been shown to co-regulate Trpm3 and Mir204
during mouse eye development, and an evolutionarily conserved
mechanism has been described in medaka fish [40–42]. Up-
regulation of miR-204 results in suppression of several target genes
involved in neurogenesis, cell-motility, and epithelial-to-mesen-
chymal transition (EMT), consistent with a role in determining
and/or maintaining epithelial cell fate [43,44]. By contrast, the
precise function(s) of Trpm3 up-regulation in ocular tissues
remains unclear. TRPM3 has been shown to function in vitro as
a spontaneous, steroid-activated, Ca2+-permeable channel, with
selectivity for other cations influenced by alternative splicing
[45,46]. In vivo, TRPM3 channel activity has been found to
facilitate diverse cellular processes including, insulin release by
pancreatic b-cells [47], mechano-sensing in vascular smooth
muscle cells [48], and thermo-sensing by dorsal root ganglia
neurons [49]. Recently, Trpm3-null mice were found to display an
attenuated pupillary light reflex (iris constriction) under bright
light and dim light conditions [50]. The abundant expression of
Trpm3 in the ciliary body coupled with the requirement for
Figure 4. Alternative splicing of TRPM3 transcripts in the human lens. (A) RT-PCR showing presence of transcripts for variant 9 (exon 1–5,
411 bp), variants 1–8 (exon 2–5, 414 bp) and a novel lens variant, KF987075 (EST - exon 5, 403 bp). (B) Quantitative RT-PCR showing relative copy
numbers of TRPM3 variant 9 (2.06E+01, SD 9.46E+00), variants 1–8 combined (2.76E+05, SD 2.15E+04), and lens variant KF987075 (3.17E+04, SD
8.07E+03) standardized against RPL19. TRPM3 primers used for amplification were as follows; RT1F - RT5R for variant 9, RT2F - RT5R for variants 1–8,
and ESTF - RT5R for lens variant KF987075 (Table S5).
doi:10.1371/journal.pone.0104000.g004
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sustained Ca2+ influx during ciliary muscle contraction, support
the notion that Trpm3 functions in regulating pupil constriction
[50]. In addition to pupil response, changes in the contractile state
of the ciliary muscle are known to modulate aqueous humor
outflow via the trabecular meshwork [51]. Further, the ciliary
epithelium (pigmented and non-pigmented) co-operate in the
production of aqueous humor [52]. These observations raise the
possibility that Trpm3 expression in the ciliary body may influence
intra-ocular pressure. Outside the ciliary body, the abundant
expression of Trpm3 in the lens epithelium and retinal pigment
epithelium suggests that this cation channel may also participate in
the maintenance of intracellular Ca2+ essential for preserving lens
transparency, and in the regulation of Ca2+ concentration fluxes in
the sub-retinal space that accompany light/dark transitions
[53,54].
Based on its Pax6-driven ocular expression pattern, Trpm3/
Mir204 represents an intriguing locus for eye disease. In mice,
disruption of Trpm3 results in a mild pupilary phenotype [50],
whereas, Pax6-deficiency results in a severe eye phenotype
characterized by aphakia, microphthalmia and anophthalmia
[55]. The divergent nature of these eye phenotypes reflects, in
part, contrasting loss-of-function effects associated with Mir204,
Trpm3 and Pax6. In Trpm3-null mice the gene-targeting site is
located in exon-17 [49], well downstream from Mir204 located in
intron-8, and would not be expected to interfere with ocular
expression of the miR-204 transcript. By contrast, early ocular
expression of both Mir204 and Trpm3 is lost in Pax6-null mice
[40]. Further, ocular defects resulting from Trpm3 loss-of-function
may be partially rescued because of functional redundancy with
other TRP(M) channels expressed in the eye. For example,
Trpm1, which shares ,57% amino acid identity with Trpm3 at
the protein level, is also expressed in the ciliary body [56].
Conversely, the severe ocular defects resulting from Pax6-
deficiency cannot be functionally rescued by other ocular
transcription factors.
In humans, rare deletions involving TRPM3 have been
reported in one case of Kabuki syndrome (KS, OMIM 147920),
and in a nuclear family with two cases of autism [23,24]. In the
autism family, a paternal deletion of exons 1–9 that included
MIR204 was shared by two affected sons and an unaffected
daughter [24]. However, no rare variants were found in the
maternal copy of TRPM3/MIR204 in the affected sons. Since
ocular abnormalities were not reported in the autism family, and
we do not have any evidence of autism in the family studied here,
the role of TRPM3 in autism remains unclear. By contrast, ocular
abnormalities have been found in about 30–50% of KS cases [57].
Typical ocular findings include ptosis, strabismus and/or blue
sclerae, whereas, less common findings include cataract, Peters’
Figure 5. Transient expression of a TRPM3-GFP fusion product in HEK293T cells. (A) N-terminal amino-acid sequence of TRPM3 isoform k
(NP_001007472), and a lens abundant isoform (KF987075). The sequence coding for amino-acids 60-153 (exon 3) of isoform k (codons 3–96 of the
lens isoform) that was inserted into the GFP fusion vector is shaded grey. The p.I65M substitution in isoform k (p.I8M in the lens isoform) is shown in
red. Translation initiator methionine residues are shown in bold and underlined. The translation start-site for isoform k is located 57 codons upstream
of that for the lens isoform, and 153 codons upstream of that for isoforms 1–8. Italics denote the 17 amino-acid sequence linking the TRPM3
sequence in-frame to GFP (green box). The GFP translation start-site is located in-frame 106 codons downstream from the I-to-M substitution in
isoform k and the lens isoform. (:) denotes identical amino-acids, (‘) indicates intron boundaries between exons 1, 3 and 4 (exon 2 is skipped). The
CaM binding domain is underlined. (B) Immunoblot analysis of transfected HEK293T cell lysates showing presence of the predicted TRPM3-GFP fusion
product (,39 kDa) that is ,12 kDa larger than native GFP (27 kDa). (*) indicates non-specific cross-reaction with the HEK293T cell lysate.
doi:10.1371/journal.pone.0104000.g005
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anomaly, corneal opacities and colobomas. Again, we have no
evidence of KS in the family studied here, and the importance of
TRPM3 in the etiology of KS is further obscured since the
majority of KS patients have been found to harbor mutations in
MLL2 on chromosome 12q [58]. Interestingly, PAX6 mutations
primarily result in a variable pan-ocular phenotype that includes
aniridia (iris hypoplasia), cataract, glaucoma, corneal clouding,
foveal dysplasia, and optic nerve hypoplasia [59,60]. In addition to
cataract and glaucoma, the TRPM3 mutation (I-to-M) discovered
here was associated with a mild iris anomaly in three affected
family members (V:3, V:4, V9), and in one case (V:9) anterior
segment dysgenesis was also documented (Figure 1b, Table S1).
Such overlap in the ocular phenotype associated with TRPM3
and PAX6mutations is consistent with the close functional synergy
between these genes during eye development. Our data predict
that the I-to-M coding mutation in TRPM3 affects the N-terminal
translation of multiple TRPM3 isoforms (Figure 5) potentially
resulting in deleterious gain-of-function effects that manifest
differently to loss-of-function effects in Trpm3-null mice. In
addition, the I-to-M mutation is located upstream of the human
MIR204 homolog hosted in intron-8 of TRPM3 (Figure 3a) and,
although it is unlikely, we cannot rule out a deleterious effect on
the ocular expression of MIR204. Further insights regarding the
genotype-phenotype complexity associated with TRPM3 await
the discovery of additional disease causing mutations associated
with this cation entry channel.
Materials and Methods
Ethics statement
Ethical approval for this study was obtained from the
Washington University Human Research Protection Office
(HRPO), and written informed consent was provided by all
participants prior to enrollment in accordance with the tenets of
the Declaration of Helsinki, and Health Insurance Portability and
Accountability Act (HIPAA) regulations.
Family participants
A 5-generation Caucasian-American pedigree segregating
cataract and glaucoma was ascertained through medical records
in the Department of Ophthalmology and Visual Sciences at
Washington University School of Medicine (Figure 1a). Retro-
spective review of medical records limited our diagnoses of
cataract and glaucoma to various lens opacities requiring surgical
extraction for visual rehabilitation, and significant elevation of
intraocular pressure (IOP.30 mm Hg) associated with or at high
risk for optic nerve damage and/or visual field loss, respectively.
Blood samples were obtained from 36 family members including
25 affected, seven unaffected, two undiagnosed and two spouses
(Table S1). Leukocyte genomic DNA was purified using the
Gentra Puregene Blood kit (Qiagen, Valencia, CA), and quantified
by absorbance at 260 nm (NanoDrop 2000, Wilmington, DE).
SNP genotyping and linkage analysis
For genome-wide linkage analysis, genotyping was performed
by means of the HumanLinkage-12 genotyping beadchip and the
Infinium-II whole-genome amplification and single-base extension
assay (Illumina, San Diego CA), in the Genome Technology
Access Center (GTAC) at Washington University. Two-point and
multipoint parametric linkage analysis was performed with
Superlink (v. 1.6) and GeneHunter (v. 2.1r5), respectively, from
the easyLINKAGE Plus (v. 5.08) package of programs (http://
genetik.charite.de/hoffmann/easyLINKAGE/). SNP marker al-
lele frequencies used for linkage analysis were those calculated for
Caucasians by the HapMap project (http://www.hapmap.org/).
A frequency of 0.001 and a penetrance of 100% were assumed for
the disease allele. Multipoint computation was performed with
GeneHunter in sets of 100 markers.
Microsatellite genotyping and linkage analysis
Microsatellite markers from the National Center for Biotech-
nology Information (NCBI) combined Ge´ne´thon, Marshfield, and
deCODE genetic linkage maps (http://www.ncbi.nlm.nih.gov/
genome/guide/human/) were genotyped by means of a 4200
DNA analyzer running Gene ImagIR software (Li-Cor, Lincoln,
NE) as described [61]. Pedigree and haploptype data were
managed using Cyrillic (v. 2.1) software (FamilyGenetix Ltd.,
Reading, UK), and two-point LOD scores (Z) calculated using the
MLINK sub-program from the LINKAGE (5.1) package of
programs (http://linkage.rockefeller.edu/soft/). Marker allele
frequencies were assumed to be equal. A frequency of 0.01%
and a penetrance of 100% were assumed for the disease allele.
Whole exome and custom-target capture
Whole exome capture was achieved using the SureSelect
Human All Exon 50 Mb Kit (Agilent Technologies), and
custom-target capture was performed with the SureSelect Target
Enrichment Kit (Agilent) and oligo-probes designed using the web-
based eArray application (http://www.genomics.agilent.com/en/
Custom-Design-Tools/eArray/?cid=AG-PT-122&tabId=AG-PR-
1047), according to manufacturer’s instructions. Briefly, genomic
DNA (3 ug) was fragmented (150–200 bp) by acoustic shearing,
ligated to adapter primers, and PCR-amplified. Following
denaturation (95uC, 5 min), amplified DNA-fragment libraries
(,500 ng) were hybridized in solution under high stringency
(65uC, 24 hr) with biotinylated RNA capture probes (,120 bp).
Resulting DNA/RNA hybrids were recovered by streptavidin-
coated magnetic bead separation (Dynal, Invitrogen) and captured
DNA eluted (NaOH) prior to next-generation sequencing.
Next-generation sequencing
Solid-phase (flow-cell) massively parallel sequencing was
performed on a HiSeq2000 System (Illumina) using the Illumina
Multiplexing Sample Preparation Oligo-nucleotide Kit, and the
HiSeq 2000 Paired-End Cluster Generation Kit according to the
manufacturers instructions. Briefly, hybrid-capture libraries were
amplified to add indexing (identifying) tags and sequencing
primers then subject to paired-end (26101 bp read length),
multiplex sequencing-by-synthesis using fluorescent reversible
(39-blocked) terminators. Raw sequence data was aligned to the
reference genome by NovoalignMPI (www.novocraft.com), and
sequence variants called using the Sequence Alignment/Map
format (SAMtools) and Picard programs (http://samtools.
sourceforge.net/), and further annotated using SeattleSeq
(http://snp.gs.washington.edu/SeattleSeqAnnotation131/). Tar-
get coverage and read depth were reviewed by the Integrated
Genomics Viewer (IGV, http://www.broadinstitute.org/igv/).
Variants were reviewed for presence/absence in dbSNP and
1000_genomes databases, frequency in the Exome Variant
Server/database (http://evs.gs.washington.edu/EVS/), and pre-
dicted effect on protein function using the PolyPhen2 and SIFT
servers [62,63].
Sanger Sequencing
Genomic sequence for TRPM3 (Gene ID: 80036) was obtained
from the Ensembl human genome browser (http://www.ensembl.
org/index.html), and gene-specific M13-tailed PCR primers
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(Table S4) were selected from the NCBI re-sequencing amplicon
(RSA) probe database (http://www.ncbi.nlm.nih.gov/sites/
entrez?db = probe) or custom designed with Primer Quest
(IDT.com) or Exon Primer (UCSC Genome Bioinformatics -
http://genome.ucsc.edu). Genomic DNA (2.5 ng/ul, 20 ul reac-
tions), was amplified (35–40 cycles) in a GeneAmp 9700 thermal
cycler using AmpliTaq polymerase (Applied Biosystems, Foster
City, CA) and gene-specific primers (10 pmol). Resulting PCR
amplicons were either enzyme-purified with ExoSAP-IT (USB
Corporation, Cleveland, OH) or gel-purified with the QIAquick
gel-extraction kit (Qiagen). Purified amplicons were direct cycle-
sequenced in both directions with BigDye Terminator Ready
Reaction Mix (v3.1) containing M13 forward or reverse
sequencing primers then ethanol precipitated and detected by
capillary electrophoresis on a 3130xl Genetic Analyzer running
Sequence Analysis (v5.2) software (Applied Biosystems), and
Chromas (v2.23) software (Technelysium, Tewantin, Queensland,
Australia).
RT-PCR
Postmortem human lens total RNA was isolated with Trizol
Reagent (Invitrogen), and reverse transcribed into cDNA by
random priming with the iScript cDNA Synthesis Kit (Bio-Rad).
TRPM3 sequence located between exon 1 and exon 5 was
amplified with AmpliTaq polymerase (Applied Biosystems) and
TRPM3 gene-specific primers (Table S5). Sequence identity was
confirmed by Sanger sequencing as above. For quantization
purposes, RT-PCR products were amplified in a 10-fold dilution
series (in triplicate) by means of the iQ SYBR green Supermix
(Bio-Rad) in a real-time PCR detection system (iQ5, Bio-Rad).
Transcript copy number was determined by melt-curve analysis
and standardization against a control transcript (RPL19) that was
amplified separately in a similar 10-fold dilution series of the same
RT-PCR products using RPL19 gene-specific forward (59-
catccgcaagcctgtgac) and reverse (59-gtgaccttctctggcattcg) primers.
59-RACE
Rapid amplification of 59-cDNA ends was achieved using the
GeneRacer Kit (Invitrogen). Briefly, total lens RNA (1–5 ug) was
dephosphorylated (CIP), decapped (TAP), and ligated to the
GeneRacer RNA oligo with T4 RNA ligase then reverse
transcribed with AMV-RT and random primers. First-strand
cDNA was PCR amplified using the GeneRacer 59-primer and a
reverse TRPM3 gene-specific primer and then re-amplified using
nested primers (Table S5) to increase product specificity and yield.
Following purification (SNAP column), resulting 59-RACE prod-
ucts with 39A-overhangs were sub-cloned into pCR4-TOPO and
Sanger sequenced in both directions using flanking T7 and T3
sequencing primers.
GFP fusion product
Generation of a C-terminal TRPM3-GFP fusion product was
achieved using the GFP Fusion TOPO TA Expression Kit
(Invitrogen) according to the manufacturer’s instructions. Briefly,
lens total RNA (1 ug) was reverse transcribed into cDNA by
random priming with the iScript cDNA Synthesis Kit (Bio-Rad).
TRPM3 coding sequence located between codons 60–154 of
isoform-k (Figure 5) was PCR amplified using either a wild-type
(I65) or mutant (M65) forward primer located in exon-3 paired
with a reverse anchor primer located in exon-4 (Table S5). PCR
product (283 bp) with non-template 39-A overhang was ligated to
the C-terminal fusion vector (pcDNA3.1/CT-GFP-TOPO) using
topoisomerase. Following transformation of competent TOP10
cells, plasmid DNA was purified from overnight cultures by the
QIAprep Spin Kit (Qiagen), and Sanger sequenced using the T7
and GFP-reverse sequencing primers to verify correct orientation
and reading frame.
Cell culture and transfection
HEK293T cells were cultured (37uC, 5% CO2) in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 2 mM
glutamine, 100 IU penicillin, 100 ug streptomycin (Cellgro,
Mediatech, Manassas, VA), and 10% bovine serum (Invitrogen).
Plasmid DNA (8 ug) was transfected into HEK293T cell
monolayers in 60 mm dishes (60–80% confluence) using Lipo-
fectamine 2000 reagent (Invitrogen) in serum-free media (Opti-
MEM, Invitrogen) for 4 hr and then cultured for 24–48 hr in
serum supplemented media. Transfected cells were washed (PBS),
detached (EDTA), and centrifuged (15006g, 5 min).
Immunoblot analysis
Transfected cell pellets were re-suspended (50 ul, 37uC, 10 min)
in detergent lysis buffer (1% IGEPAL, 50 mM Tris-HCL,
150 mM NaCl, pH 7.8; Sigma) then centrifuged (10,0006g,
10 min) to pellet cell nuclei. Post-nuclear lysate was removed and
soluble protein concentration was determined using the Non-
interfering assay (G-Bioscience). Soluble proteins (20 ug) were
separated on SDS-PAGE gels (12%) then transferred onto
nitrocellulose, incubated with anti-GFP rabbit serum (Invitrogen,
dil 1:1000), and visualized using an Odyssey Infrared Imaging
System (Li-Cor Bioscience).
Supporting Information
Figure S1 Genome-wide linkage analysis of ocular
disease in the family using SNP markers. (A) Parametric
two-point LOD scores (pLOD SPT) indicating linkage to
chromosome 9. (B) Parametric multi-point LOD scores (pLOD
MPT) confirming linkage to chromosome 9.
(TIF)
Figure S2 N-terminal reading frame of the novel lens
abundant TRPM3 transcript (KF987075) detected in
Figure 4. A previously identified lens EST (BM712132) [30] is
shaded grey. The predicted translation initiator methionine is
shown in bold. Note, the translation initiator methionine for
transcript variants 1–8 is located 97 codons downstream (bold
underlined). The I8 M mutation site is shown in red. Upstream
translation stop-codons, in-frame with the translation start-codons,
are shown in italics. Paired PCR primer sequences (Table S5)
located in the EST and in exon 10 are underlined. (‘) indicates
intron boundaries between the EST and exons 3, 4, 5, 6, 7, and 9
(exon 8 is skipped).
(TIFF)
Figure S3 N-terminal coding sequence of TRPM3 that
was used to generate a GFP fusion product (Figure 5).
Note the A-to-G missense change (I-to-M substitution) is
embedded in a partially consensus Kozak translation start-site
(TGG ATG G). Several potential out-of-frame translation start-
sites are located between the predicted I-to-M substitution site
(red) and the consensus Kozak start-site for GFP (A/GNN ATG
G). Vector sequence is shown in italics.
(TIF)
Table S1 Clinical ocular status of affected individuals
in the family.
(XLSX)
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Table S2 SNP haplotype for the ocular disease locus on
chromosome 9.
(DOCX)
Table S3 Transcript variants of TRPM3 derived from
alternative splicing.
(XLSX)
Table S4 PCR primers for Sanger sequencing of
TRPM3 exons.
(DOCX)
Table S5 RT-PCR primers for amplification of TRPM3
cDNA.
(DOCX)
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